Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol Finds Biomarkers For Improved Response To Orencia In RA

This article was originally published in The Pink Sheet Daily

Executive Summary

Rheumatoid arthritis patients treated with Bristol’s Orencia who tested positive for two biomarkers of poor prognosis had a significantly greater response on outcomes than those who did not in a real-world data analysis presented at EULAR. The experience with TNF inhibitors was different.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register